Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel
Sign Up to like & getrecommendations! Published in 2020 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-020-05320-4
Abstract: Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in… read more here.
Keywords: real world; sharing real; olaparib toxicities; management ... See more keywords